Slide 1: Intimation of Investor Presentation to Stock Exchanges
INNOVA CAPTAB LIMITED 1281/1, Hilltop Industrial Estate, Near EPIP, Phase-I, Jharmajri, Baddi, Dist. Solan (H.P.)-173205 India. Phone: +91-1795-650820 07th August, 2025 To, To, BSE Limited National Stock Exchange of India Limited Phiroze Jeejeebhoy Towers, Exchange Plaza, 5th Floor Dalal Street, Mum
Slide 2: Excelling with Passion, Powering Potential
Excelling with Passion Powering Potential Investor Presentation - 7th August 2025
Slide 3: Safe Harbor
Safe Harbor This presentation and the accompanying slides (the “Presentation”), which have been prepared by Innova Captab Limited (the “Company”), have been prepared solely for information purposes and do not constitute any offer, recommendation or invitation to purchase or subscribe for any securit
Slide 4: Company Overview
Company Overview
Slide 5: Leading Pharmaceutical Player with Comprehensive Business Model
Leading Pharmaceutical Player with Comprehensive Business Model Robust Financials Preferred CDMO partner for prominent pharmaceutical companies worldwide, with a strong direct (FY25) presence across geographies through our branded generics business Revenues ₹ 1,244 Cr EBITDA 300 + Presence across 60
Slide 6: Regrouping of Business Areas
Regrouping of Business Areas Reorganized into two focused verticals - CDMO and Branded Generics Business Robust Financials (FY25*) CDMO Sharon Bio-Medicine CDMO Part of International Reorganised Branded Generics Branded Generics Domestic Branded Generics Part of International Branded Generics 05
Slide 7: With State-of-the-Art Manufacturing Facilities
With State-of-the-Art Manufacturing Facilities Key Accreditations 9 Manufacturing Blocks Kathua, Jammu [4 Blocks] 3 Baddi |1 Dehradun |1 Taloja | 4 Jammu Upcoming R&D Baddi, Himachal Pradesh (2 Units) [3 Blocks] Facility in R&D Facility in Baddi, Himachal Pradesh Panchkula, Haryana Dehradun, Uttarak
Slide 8: Journey of Achieving Major Milestones
Journey of Achieving Major Milestones Acquisition of Sharon • Innova Captab began its • Received GMP Certificate for • Acquisition of Sharon, through the journey in 2006 with the cephalosporin products from • Further expanded the G block Corporate Insolvency Resolution Process establishment of first
Slide 9: Q1 FY26 Performance Highlights
Q1 FY26 Performance Highlights
Slide 10: MD's Commentary
MD’s Commentary The first quarter has provided us with a strong and confident start to the financial year 2026. We delivered solid growth, reflected in both a healthy expansion of our topline and a notable improvement in operating profitability. We continued to make steady progress on our strategic
Slide 11: Q1 FY26 Performance Highlights - Revenue
Q1 FY26 Performance Highlights - Revenue Revenue (₹ Crore) +19% Revenue from Operations recorded robust growth of 19% year-on-year, 351.5 reaching ₹ 351.5 crore in Q1 FY26, driven by introduction of new products 294.3 (including that from newly commissioned Jammu plant) and market expansion • CDMO b
Slide 12: Q1 FY26 Performance Highlights - Profitability
Q1 FY26 Performance Highlights - Profitability EBITDA (₹ crore) 15.1% 16.1% Margin +28% 56.6 • Consolidated EBITDA stood at ₹ 56.6 crore vs ₹ 44.3 crore in Q1 FY25 44.3 signifying solid YoY growth of 28% • EBITDA margins improved to 16.1% vs 15.1% in Q1 FY25, mainly supported by expanded gross margi
Slide 13: Consolidated Profit & Loss Statement
Consolidated Profit & Loss Statement Profit and Loss (₹ crore) Q1 FY26 Q1 FY25 YoY Growth FY25 FY24 YoY Growth Revenue from Operations 351.5 294.3 19.5% 1,243.7 1,081.3 15.0% Other Income 4.5 2.1 12.0 12.5 Total Income 356.0 296.4 20.1% 1,255.7 1,093.8 14.8% Cost of Material Consumed 220.7 199.2 814
Slide 14: Key Strengths
Key Strengths
Slide 15: Building on Core Strengths, Unlocking Future Growth
Building on Core Strengths, Unlocking Future Growth Extensive Product Offerings, Wider Reach, R&D Centric Organization Stronger Future Comprehensive Business Experienced Promoters and Model Board of Directors Relentless Expansion of Consistent Financial Manufacturing Capabilities: Performance Fuel f
Slide 16: Relentless Expansion of Manufacturing Capabilities (1/3)
Relentless Expansion of Manufacturing Capabilities: Fuel for Sustained Growth (1/3) Annualized Installed Capacity Jammu Plant Dehradun & Taloja Plant Baddi Plant Expansion through New Greenfield Project Expansion through Inorganic 2025 onwards Acquisition Tablets 10,679 mn Building blocks for growth
Slide 17: Capacity Expansion in Jammu (2/3)
Capacity Expansion in Jammu (2/3) Eligible for following benefits via Central Government's 'New Central Sector Scheme ₹ 480+ crore GST-linked incentive tune of 300% of investment to the Capital Interest Subvention of 6% per Total Capital Investment made in eligible plant and annum on loan against ma
Slide 18: Growth led by Capacity Expansion (3/3)
Growth led by Capacity Expansion (3/3) Baddi Plant Dehradun & Taloja Plant Jammu Plant 15% - 20% 15% - 20% 20%-30% 70% - 75% 40%-50% 70%-75% 70% - 75% 50% - 55% 50% - 60% FY25 Un-utilized Capacity Optimum Utilization FY25 Un-utilized Capacity Optimum Utilization Commenced Ramp up in Further Optimum
Slide 19: Comprehensive Business Model
Comprehensive Business Model CDMO Services and Products 3,700 + Products • Preferred partner for companies seeking to efficiently deliver high-quality medicines to market 300 + • Wide range of dosage forms, including oral solids, oral liquids, dry CDMO Customers syrups, dry powder injectables, paren
Slide 20: Extensive Product Offerings, Wider Reach, Stronger Future
Extensive Product Offerings, Wider Reach, Stronger Future FY21 FY25 Ongoing development of various formulations will drive Number of Products 1,000 + 3,700 + continued enhancement of product offerings 119 300+ Focus on consistently adding new clients, with sustained efforts to effectively service th
Slide 21: R&D Focused Organisation and R&D Laboratory
R&D Focused Organisation 40 + R&D Laboratory Scientist & Engineers Baddi, Himachal Pradesh Robust Research and Development • Dedicated R&D facility and pilot equipment located in Baddi, Himachal Pradesh, recognized by the DSIR for its in-house R&D work • State-of-the-art facility equipped with a com
Slide 22: Experienced Promoters and Board of Directors
Experienced Promoters and Board of Directors Mr. Manoj Kumar Lohariwala Mr. Vinay Lohariwala Mr. Jayant Vasudeo Rao Mr. Archit Aggarwal Chairman and Whole-Time Director Managing Director Whole-Time Director Non-Executive Non-Independent Director Mr. Sudhir Kumar Bassi Ms. Priyanka Dixit Sibal Mr. Ma
Slide 23: Consistent Financial Performance
Consistent Financial Performance Revenue from Operations EBITDA (₹ crore) PAT (₹ crore) (₹ crore) 13.6% 12.4% 13.3% 15.4% 15.9% 8.4% 8.0% 7.3% 8.7% 10.3% Margin +32% 1,244 1,081 198 926 +37% 167 801 128 +38% 123 99 94 411 64 68 56 35 FY21 FY22 FY23 FY24 FY25 FY21 FY22 FY23 FY24 FY25 FY21 FY22 FY23 F
Slide 24: Historical Financial Performance
Historical Financial Performance
Slide 25: Consolidated Profit & Loss Statement
Consolidated Profit & Loss Statement Profit and Loss (₹ crore) FY25 FY24 FY23 FY22 FY21 Revenue from Operations 1,243.7 1,081.3 926.4 800.5 410.7 Other Income 12.0 12.5 9.2 2.9 1.4 Total Revenue 1,255.7 1,093.8 935.6 803.4 412.0 Cost of Materials Consumed 814.1 728.3 691.6 617.9 310.7 Employee Cost
Slide 26: Consolidated Balance Sheet
Consolidated Balance Sheet Assets (₹ crore) FY25 FY24 FY23 FY22 FY21 Equity & Liabilities (₹ crore) FY25 FY24 FY23 FY22 FY21 Non - Current Assets 877.3 741.1 261.9 196.4 99.1 Total Equity 959.4 830.9 276.5 208.6 144.8 Property, plant and equipment 766.9 291.6 150.1 156.6 76.4 Share Capital 57.2 57.2
Slide 27: Consolidated Cash Flow
Consolidated Cash Flow Particulars (₹ crore) FY25 FY24 FY23 FY22 FY21 Net Profit Before Tax 171.0 129.5 91.8 85.7 46.3 Adjustments for: Non -Cash Items / Other Investment or Financial Items (31.3) (37.3) (25.9) (15.3) (9.6) Operating profit before working capital changes 202.3 166.8 117.7 101.0 55.9
Slide 28: Thank You!
Thank You! Innova Captab Limited : Investor Relations Advisor : http://www.sgapl.net/images/sgapl_logo.jpg Strategic Growth Advisors Pvt. Ltd. Innova Captab Ltd. CIN - U74140MH2010PTC204285 CIN – L24246MH2005PLC150371 Ms. Shaily Patwa / Mr. Shrikant Sangani Mr. Lokesh Bhasin/ Mr. Ayush Kumar Garg Em